Pre-irradiation chemotherapy in high risk medulloblastoma.

The present study evaluates the effect of pre-irradiation chemotherapy in pediatric patients with high risk medulloblastoma. Twenty-four (24) pediatric patients attended the pediatric unit of Kasr-El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 2000 to January 2003.
Our patients were 13 boys and 11 girls aged 3-12 years with a median of 6.5 years. According to Chang staging system 6 cases had T2, 14 cases had T3 A and 4 cases had T3 B, 20 cases were M0, 3 cases were M1 and 1 case was M2. All patients were treated by initial surgery, 2 cycles of pre-irradiation chemotherapy followed by craniospinal radiation then by 4 cycles of post-radiation chemotherapy.
Fifteen out of the 20 patients with M0 had objective response (10CR + 5PR) and no one had disease progression after pre-irradiation chemotherapy. Among 4 patients with M0 disease, 2 patients had PR and 2 had S.D. There was no disease progression among patients who received pre-irradiation chemotherapy. The 3-year overall survival and 3-year progression-free survival; (PFS) were 50% and 51%, respectively, Myelosuppression was the main toxic effect observed during pre-irradiation chemotherapy; however, there was no delay or interruption of craniospinal irradiation.
Pre-irradiation chemotherapy is effective in high risk medulloblastoma and is associated with acceptable side effects. The delay in craniospinal irradiation (CSI) for about 5 weeks to receive 2 courses of chemotherapy will not significantly increase disease progression. Multiple cycles of post-irradiation chemotherapy can be given safely after CSI. A larger number of patients and longer follow-up is needed to confirm the results.
AuthorsHesham H Abd-El-Aal
JournalJournal of the Egyptian National Cancer Institute (J Egypt Natl Canc Inst) Vol. 18 Issue 4 Pg. 357-62 (Dec 2006) ISSN: 1110-0362 [Print] Egypt
PMID18301459 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Etoposide
  • Cisplatin
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cerebellar Neoplasms (drug therapy, etiology, mortality, radiotherapy)
  • Child
  • Child, Preschool
  • Cisplatin (administration & dosage, adverse effects)
  • Combined Modality Therapy
  • Etoposide (administration & dosage, adverse effects)
  • Female
  • Humans
  • Male
  • Medulloblastoma (drug therapy, etiology, mortality, radiotherapy)
  • Radiotherapy
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: